Skip to main content

Table 1 Long-term follow-up analysis

From: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

Individual patient number Cancer stage prior to treatment 1 year 1.5 year 2 years 3 years
TNM AJCC     
Panagen group
02-01 T4NxM0 IIIB ND1 Alive Alive Progression. Metastases in lungs
02-02 T2N0M0 IIA Remission Remission Remission ND
02-03 T1N1M0 IIA Remission Remission Remission Progression. Metastases in Th11
02-04 T3N2M1 IV Deceased. Cause: breast cancer - - -
02-05 T4N1M0 IIIB Remission Remission Remission ND
02-06 T4NxM1 IV Deceased. Cause: breast cancer - - -
02-08 T4N1M0 IIIB Remission Remission Remission ND
02-09 T1N1M0 IIA Progression. Bone metastases (detected after 1st chemotherapy) Alive Alive ND
02-10 T1N1M0 IIA Remission Remission Remission Remission
02-11* T2N1M0 IIB Remission Remission Remission Remission
02-14 T2N2M0dex T4N1M0sin IIIB Remission Remission Remission Remission
02-15 T3N2M0 IIIA Remission Remission Remission Remission
02-16* T4NxM0 IIIB Remission Cancer relapse. Skin metastases around scar tissue Partial regression ND
02-18* T4NxM0 IIIB ND Alive Alive ND
02-20 T2N1M0 IIB Remission Remission Remission  
02-21 T2N0M0 IIA Remission Remission Remission  
02-22* T2N1M0 IIB Remission Remission Remission  
02-24 T2N1M0 IIB Remission Remission Remission  
02-25* T2N2M0 IIIA Remission Remission Remission  
02-26 T1N1M0 IIA Remission Remission Remission  
02-27 T1N2M0 IIIA Remission Remission ND  
02-28* T2N1M0 IIB Remission Remission ND  
02-29 T2N0M0 IIA Remission Remission ND  
02-30 T2NxM0 II Remission Remission Remission  
02-31 T2N1M0 IIB Progression. Metastases in lungs Alive Alive  
02-33* T2N3M0 IIIC Remission ND ND  
02-36 T4NxM0dex T2NxM0sin IIIB Treatment is on-going due to chemotherapy scheduling issues Treatment in progress ND  
02-39 T2N3M0 IIIC Remission Remission Remission  
02-40* T2N1M0 IIB Remission ND ND  
02-42* T1N3M0 IIIC Remission Remission Remission  
02-43 T3N0M0 IIB Remission Remission Remission  
02-44* T1N1M0 IIA Progression. Bone metastases (detected after 2nd chemotherapy) ND ND  
02-45* T4N1M0 IIIB Remission Remission Remission  
Final outcome Progression or death in 8 out of 33 patients (24%)   
Placebo group
02-07 T4N2M0 IIIB Deceased. Cause: breast cancer - - -
02-12* T2N2M0 IIIA Remission Remission Remission ND
02-13 T4N3M0 IIIC Treatment in progress Progression. Metastases in lungs ND ND
02-17 T2N1M0 IIB Remission Remission Remission Remission
02-23* T2N1M0 IIB Progression. Bone metastases Alive ND  
02-32 T4NxM0 IIIB ND ND ND  
02-34 T4N2M0 IIIB ND ND ND  
02-35* T4NxM0 IIIB Remission Remission Progression. Metastases in brain  
02-37* T4N0M0 IIIB Progression. Metastases in brain, lungs, liver and bones ND ND  
02-38 T2N2M0 IIIA ND ND ND  
02-41 T1N1M0 IIA Remission Remission Remission  
Final outcome Progression or death in 5 out of 11 patients (45%)
  1. Note: Cancer progression (metastatic disease or patient death) is highlighted by boldface.
  2. 1– ND – no data available.
  3. *– estrogen-dependent tumors.